Mumbai, Aug. 12 -- The growth in revenue from operations was fueled by the US market, with contributions from new product launches in the gastrointestinal, pain management, and digestive health segments

Profit before tax (PBT) declined 36.18% YoY to Rs 76.59 crore during the quarter.

EBITDA slipped 22% to Rs 100.1 crore in Q1 June 2025, compared with Rs 128.4 crore posted in Q1 June 2024. EBITDA margin fell 560 bps to 16.1% in Q1 FY26 as against 21.7% in Q1 FY25.

During the quarter, revenue from US & North America stood at Rs 327.6 crore (up 30.6% YoY) while revenue from UK and Europe stood at Rs 203.8 crore (down 19% YoY).

Revenue from Australia and New Zealand business stood at Rs 57 crore (down 13.1% YoY) in Q1 FY26. Rest of World ...